US Stock MarketDetailed Quotes

FATE Fate Therapeutics

Watchlist
  • 3.800
  • -0.070-1.81%
Close Apr 26 16:00 ET
  • 3.880
  • +0.080+2.11%
Post 17:42 ET
432.38MMarket Cap-2317P/E (TTM)

About Fate Therapeutics Company

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Company Profile

SymbolFATE
Company NameFate Therapeutics
Listing DateOct 1, 2013
Issue Price6.00
Founded2007
CEOMr. J. Scott Wolchko
MarketNASDAQ
Employees220
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address12278 Scripps Summit Drive
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92131
Phone1-858-875-1800
Websitehttp://www.fatetherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • J. Scott Wolchko
  • Director, Chief Executive Officer and President
  • 11.73M
  • Brian T. Powl
  • Chief Commercial Officer
  • --
  • Dr. Bahram Valamehr, PhD
  • Chief Research and Development Officer
  • 6.48M
  • Edward J. Dulac, III
  • Chief Financial Officer and Principal Accounting Officer
  • 6.38M
  • Dr. John D. Mendlein, J.D.,PhD
  • Vice Chairman of the Board
  • 442.05K
  • Dr. William H. Rastetter,PhD
  • Chairman of the Board
  • 466.05K
  • Timothy P. Coughlin
  • Independent Director
  • 445.55K
  • Michael Lee
  • Independent Director
  • 430.55K
  • Dr. Karin Jooss, PhD
  • Independent Director
  • 436.30K
  • Dr. Yuan Xu, PhD
  • Independent Director
  • 811.84K
  • Dr. Shefali Agarwal
  • Independent Director
  • 440.92K
  • Dr. Robert M. Hershberg, M.D.,PhD
  • Independent Director
  • 435.17K
  • Dr. Robert S. Epstein, M.D.,M.S.
  • Independent Director
  • 441.55K
  • Cindy Tahl
  • General Counsel and Corporate Secretary
  • 6.48M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg